Selumetinib Shrinks Pediatric Tumors, Results of an Early-Phase Clinical Trial
Brigitte C. Widemann, M.D., acting chief of the National Cancer Institute’s (NCI) Pediatric Oncology Branch, discusses the results of her phase 1 trial, which evaluated the toxicity and safety of selumetinib in patients with the common genetic disorder neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas.
![](/sites/g/files/xnrzdm211/files/oembed_thumbnails/iH5Sz5nSs9i0dyU92BYaC_RO1IREyfAxxQpuWbuIk20.jpg)
Selumetinib Shrinks Pediatric Tumors, Results of an Early-Phase Clinical Trial